Somavert
(Pegvisomant)PreclinicalSmall molecule
Pegvisomant is used to treat acromegaly, a condition where the body produces too much growth hormone, causing abnormal growth of hands, feet, and facial features. It works by blocking the effects of growth hormone in the body.[1] Somavert is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]
Somavert is one of 61 small molecule programs targeting Growth Hormone Deficiency. It is currently in Preclinical.
4
Indications
26
Total Trials
1
Active Trials
60
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Dexilant
TakedaPreclinical
Niclocide
BayerPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Clomid
FerringPreclinical
Aurlumyn
BBTG International Inc.
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acromegaly8 trials
Bone MicroArchitecture in Acromegaly
Completed·—··NCT03225040·77 enrolled
Show 5 more trials
Acromegaly Combination Treatment Study
Terminated·—·N/A·NCT01538966·76 enrolled
Growth5 trials
Show 2 more trials
Biomarker1 trial
Tissue Biomarker for Pegvisomant Action
Completed·—·N/A·NCT01261000·8 enrolled
Efficacy and Safety1 trial
9 more indications
Insulin Sensitivity1 trial
McCune-Albright syndrome1 trial
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 3·NCT00017927·10 enrolled
Combination Therapy1 trial
Growth Hormone Deficiency1 trial
Treatment1 trial
Quality of Life1 trial
Insulin Receptor Mutation1 trial
Phase II Study of Growth Hormone Inhibition Using Pegvisomant In Severe Insulin Resistance
Recruiting·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT05470504·25 enrolled
Regulatory
FDA Approval Timeline[4]
Mar 25, 2003
SOMAVERT
BLA BLA021106
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pegvisomant. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Growth Hormone Receptor Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPharmacia and Upjohn